SLC5A2 and diabetic kidney disease: Diabetic nephropathy is regarded as a major cause of end-stage renal disease, and true DKD usually requires treatment by glycaemic control and dual sodium-dependent glucose transporters 2 (SGLT2) and rennin angiotensin system (RAS) inhibition.